Advertisement

The Role of Drug Therapy in Lowering Mortality and Morbidity: From Established Heart Failure to High-Risk Hypertension

  • Nisha Mistry
  • Sverre E. KjeldsenEmail author
  • Arne Westheim
Chapter
Part of the Updates in Hypertension and Cardiovascular Protection book series (UHCP)

Abstract

Hypertension, untreated or insufficiently treated, is the most important cause of left ventricular hypertrophy, coronary heart disease, myocardial infarction, arrhythmias, and eventually cardiac failure whether left ventricular ejection fraction is reduced or preserved. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, beta-blockers, and mineralocorticoid receptor antagonists (aldosterone antagonists) are cornerstones in the treatment of both patients with heart failure with reduced ejection fraction and high-risk hypertension as these drug classes lower morbidity and mortality. These drugs as well as calcium antagonists can safely be used in patients with preserved ejection fraction though no drug class has been shown specifically to lower mortality. Diuretic treatment is generally considered a symptomatic treatment in heart failure patients but is needed in high-risk hypertension to control the high blood pressure and prevent complications. However, for primary prevention of heart failure in hypertensive patients, the various drug classes appear equally effective.

Keywords

Aldosterone antagonist Angiotensin-converting enzyme inhibitor Angiotensin II receptor blocker Beta-blocker Blood pressure Calcium antagonist Heart failure Hypertension 

References

  1. 1.
    Gradman AH, Alfayoumi F. From left ventricular hypertrophy to congestive heart failure: management of hypertensive heart disease. Prog Cardiovasc Dis. 2006;48(5):326–41.CrossRefGoogle Scholar
  2. 2.
    Daemen MJ, Lombardi DM, Bosman FT, Schwartz SM. Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall. Circ Res. 1991;68(2):450–6.CrossRefGoogle Scholar
  3. 3.
    Folkow B, Johansson B, Mellander S. The comparative effects of angiotensin and noradrenaline on consecutive vascular sections. Acta Physiol Scand. 1961;53:99–104.CrossRefGoogle Scholar
  4. 4.
    Zimmerman BG, Sybertz EJ, Wong PC. Interaction between sympathetic and renin-angiotensin system. J Hypertens. 1984;2(6):581–7.CrossRefGoogle Scholar
  5. 5.
    Padfield PL, Morton JJ. Effects of angiotensin II on arginine-vasopressin in physiological and pathological situations in man. J Endocrinol. 1977;74(2):251–9.CrossRefGoogle Scholar
  6. 6.
    Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129–200.CrossRefGoogle Scholar
  7. 7.
    SOLVD Investigators, Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325(5):293–302.CrossRefGoogle Scholar
  8. 8.
    CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316(23):1429–35.CrossRefGoogle Scholar
  9. 9.
    Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr, Cuddy TE, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992;327(10):669–77.CrossRefGoogle Scholar
  10. 10.
    Gustafsson F, Torp-Pedersen C, Kober L, Hildebrandt P. Effect of angiotensin converting enzyme inhibition after acute myocardial infarction in patients with arterial hypertension. TRACE Study Group, Trandolapril Cardiac Event. J Hypertens. 1997;15(7):793–8.CrossRefGoogle Scholar
  11. 11.
    Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet. 1993;342(8875):821–8.Google Scholar
  12. 12.
    Demers C, Mody A, Teo KK, McKelvie RS. ACE inhibitors in heart failure: what more do we need to know? Am J Cardiovasc Drugs. 2005;5(6):351–9.CrossRefGoogle Scholar
  13. 13.
    Burnier M. Angiotensin II type 1 receptor blockers. Circulation. 2001;103(6):904–12.CrossRefGoogle Scholar
  14. 14.
    Reed SD, Radeva JI, Weinfurt KP, McMurray JJ, Pfeffer MA, Velazquez EJ, et al. Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT). Am Heart J. 2005;150(2):323–9.CrossRefGoogle Scholar
  15. 15.
    Cohn JN, Tognoni G, Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345(23):1667–75.CrossRefGoogle Scholar
  16. 16.
    Carson P, Tognoni G, Cohn JN. Effect of Valsartan on hospitalization: results from Val-HeFT. J Card Fail. 2003;9(3):164–71.CrossRefGoogle Scholar
  17. 17.
    Maggioni AP, Latini R, Carson PE, Singh SN, Barlera S, Glazer R, et al. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J. 2005;149(3):548–57.CrossRefGoogle Scholar
  18. 18.
    Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003;362(9386):759–66.CrossRefGoogle Scholar
  19. 19.
    Hermann F, Ruschitzka FT, Schiffrin EL. Clinical trials report. CHARM-Alternative Trial. Curr Hypertens Rep. 2004;6(1):47.CrossRefGoogle Scholar
  20. 20.
    McMurray JJ, Young JB, Dunlap ME, Granger CB, Hainer J, Michelson EL, et al. Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM)-added trial. Am Heart J. 2006;151(5):985–91.CrossRefGoogle Scholar
  21. 21.
    Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003;362(9386):777–81.CrossRefGoogle Scholar
  22. 22.
    Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II. Lancet. 2000;355(9215):1582–7.CrossRefGoogle Scholar
  23. 23.
    Konstam MA, Neaton JD, Dickstein K, Drexler H, Komajda M, Martinez FA, et al. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet. 2009;374(9704):1840–8.CrossRefGoogle Scholar
  24. 24.
    Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Card Fail. 2017;23(8):628–51.CrossRefGoogle Scholar
  25. 25.
    Neutel JM, Bedigian MP. Efficacy of valsartan in patients aged > or =65 years with systolic hypertension. Clin Ther. 2000;22(8):961–9.CrossRefGoogle Scholar
  26. 26.
    Waldmeier F, Flesch G, Muller P, Winkler T, Kriemler HP, Buhlmayer P, et al. Pharmacokinetics, disposition and biotransformation of [14C]-radiolabelled valsartan in healthy male volunteers after a single oral dose. Xenobiotica. 1997;27(1):59–71.CrossRefGoogle Scholar
  27. 27.
    Billman GE, Castillo LC, Hensley J, Hohl CM, Altschuld RA. Beta2-adrenergic receptor antagonists protect against ventricular fibrillation: in vivo and in vitro evidence for enhanced sensitivity to beta2-adrenergic stimulation in animals susceptible to sudden death. Circulation. 1997;96(6):1914–22.CrossRefGoogle Scholar
  28. 28.
    Mann DL, Kent RL, Parsons B, Cooper G. Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation. 1992;85(2):790–804.CrossRefGoogle Scholar
  29. 29.
    Bristow MR. Mechanism of action of beta-blocking agents in heart failure. Am J Cardiol. 1997;80(11A):26L–40L.CrossRefGoogle Scholar
  30. 30.
    Doughty RN, MacMahon S, Sharpe N. Beta-blockers in heart failure: promising or proved? J Am Coll Cardiol. 1994;23(3):814–21.CrossRefGoogle Scholar
  31. 31.
    Eichhorn EJ, Bristow MR. Medical therapy can improve the biological properties of the chronically failing heart. A new era in the treatment of heart failure. Circulation. 1996;94(9):2285–96.CrossRefGoogle Scholar
  32. 32.
    Bellenger NG, Rajappan K, Rahman SL, Lahiri A, Raval U, Webster J, et al. Effects of carvedilol on left ventricular remodelling in chronic stable heart failure: a cardiovascular magnetic resonance study. Heart. 2004;90(7):760–4.CrossRefGoogle Scholar
  33. 33.
    Gilbert EM, Abraham WT, Olsen S, Hattler B, White M, Mealy P, et al. Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation. 1996;94(11):2817–25.CrossRefGoogle Scholar
  34. 34.
    The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353(9146):9–13.Google Scholar
  35. 35.
    Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353(9169):2001–7.Google Scholar
  36. 36.
    Packer M, Fowler MB, Roecker EB, Coats AJ, Katus HA, Krum H, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation. 2002;106(17):2194–9.CrossRefGoogle Scholar
  37. 37.
    Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A, Borbola J, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005;26(3):215–25.CrossRefGoogle Scholar
  38. 38.
    Frishman WH, Stier CT Jr. Aldosterone and aldosterone antagonism in systemic hypertension. Curr Hypertens Rep. 2004;6(3):195–200.CrossRefGoogle Scholar
  39. 39.
    Barr CS, Lang CC, Hanson J, Arnott M, Kennedy N, Struthers AD. Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol. 1995;76(17):1259–65.CrossRefGoogle Scholar
  40. 40.
    MacFadyen RJ, Barr CS, Struthers AD. Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. Cardiovasc Res. 1997;35(1):30–4.CrossRefGoogle Scholar
  41. 41.
    Wang W. Chronic administration of aldosterone depresses baroreceptor reflex function in the dog. Hypertension. 1994;24(5):571–5.CrossRefGoogle Scholar
  42. 42.
    Duprez DA, De Buyzere ML, Rietzschel ER, Taes Y, Clement DL, Morgan D, et al. Inverse relationship between aldosterone and large artery compliance in chronically treated heart failure patients. Eur Heart J. 1998;19(9):1371–6.CrossRefGoogle Scholar
  43. 43.
    Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341(10):709–17.CrossRefGoogle Scholar
  44. 44.
    Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348(14):1309–21.CrossRefGoogle Scholar
  45. 45.
    Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364(1):11–21.CrossRefGoogle Scholar
  46. 46.
    Bayliss J, Norell M, Canepa-Anson R, Sutton G, Poole-Wilson P. Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics. Br Heart J. 1987;57(1):17–22.CrossRefGoogle Scholar
  47. 47.
    Westheim AS, Bostrom P, Christensen CC, Parikka H, Rykke EO, Toivonen L. Hemodynamic and neuroendocrine effects for candoxatril and frusemide in mild stable chronic heart failure. J Am Coll Cardiol. 1999;34(6):1794–801.CrossRefGoogle Scholar
  48. 48.
    Pereira M, Lunet N, Azevedo A, Barros H. Differences in prevalence, awareness, treatment and control of hypertension between developing and developed countries. J Hypertens. 2009;27(5):963–75.CrossRefGoogle Scholar
  49. 49.
    Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol. 1993;22(4 Suppl A):6A–13A.CrossRefGoogle Scholar
  50. 50.
    Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J, et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006;27(19):2338–45.CrossRefGoogle Scholar
  51. 51.
    Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008;359(23):2456–67.CrossRefGoogle Scholar
  52. 52.
    Ahmed A, Rich MW, Fleg JL, Zile MR, Young JB, Kitzman DW, et al. Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial. Circulation. 2006;114(5):397–403.CrossRefGoogle Scholar
  53. 53.
    Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370(15):1383–92.CrossRefGoogle Scholar
  54. 54.
    Packer M, O’Connor CM, Ghali JK, Pressler ML, Carson PE, Belkin RN, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. N Engl J Med. 1996;335(15):1107–14.CrossRefGoogle Scholar
  55. 55.
    Smiseth OA. Evaluation of left ventricular diastolic function: state of the art after 35 years with Doppler assessment. J Echocardiogr. 2018;16(2):55–64.CrossRefGoogle Scholar
  56. 56.
    ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group, The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288(23):2981–97.CrossRefGoogle Scholar
  57. 57.
    Appel LJ. The verdict from ALLHAT—thiazide diuretics are the preferred initial therapy for hypertension. JAMA. 2002;288(23):3039–42.CrossRefGoogle Scholar
  58. 58.
    Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358(18):1887–98.CrossRefGoogle Scholar
  59. 59.
    SPRINT Research Group, Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373(22):2103–16.CrossRefGoogle Scholar
  60. 60.
    Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28.CrossRefGoogle Scholar
  61. 61.
    Scheen AJ. Reappraisal of the diuretic effect of empagliflozin in the EMPA-REG OUTCOME trial: comparison with classic diuretics. Diabetes Metab. 2016;42(4):224–33.CrossRefGoogle Scholar
  62. 62.
    Kosiborod M, Cavender MA, Fu AZ, Wilding JP, Khunti K, Holl RW, et al. Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL Study (comparative effectiveness of cardiovascular outcomes in new users of sodium-glucose cotransporter-2 inhibitors). Circulation. 2017;136(3):249–59.CrossRefGoogle Scholar
  63. 63.
    Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359(9311):995–1003.CrossRefGoogle Scholar
  64. 64.
    Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363(9426):2022–31.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Nisha Mistry
    • 1
    • 2
  • Sverre E. Kjeldsen
    • 1
    • 2
    Email author
  • Arne Westheim
    • 1
    • 2
  1. 1.University of Oslo, Institute for Clinical MedicineOsloNorway
  2. 2.Department of CardiologyOslo University Hospital, UllevaalOsloNorway

Personalised recommendations